Singapore markets open in 4 hours 15 minutes

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.7500-0.0500 (-1.79%)
At close: 04:00PM EDT
2.7500 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.8000
Open2.7200
Bid2.7500 x 1400
Ask2.8200 x 1000
Day's range2.7200 - 2.8500
52-week range2.0700 - 32.4900
Volume734,859
Avg. volume688,270
Market cap159.418M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.8500
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.83
  • Business Wire

    Graphite Bio Announces Participation in Jefferies Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., June 01, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4 p.m. ET.

  • Business Wire

    Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting

    SOUTH SAN FRANCISCO, Calif., May 16, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical data for GPH102, the company’s differentiated gene replacement program for beta-thalassemia, in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The hyb

  • Business Wire

    Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 12, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and first quarter 2022 financial results.